Stimlabs LLC, (“StimLabs”), a leader in regenerative medicine, announced the launch of Relese, a fenestrated dehydrated complete human placental membrane (dCHPM) allograft for chronic and acute wounds.
| ROSWELL, Ga., Aug. 24, 2023 /PRNewswire/ -- StimLabs, LLC, (“StimLabs”), a leader in regenerative medicine, announced the launch of Relese, a fenestrated dehydrated complete human placental membrane (dCHPM) allograft for chronic and acute wounds. As the latest solution in StimLabs’ growing suite of dCHPM allografts, Relese provides a selective barrier with channels that allow wound fluid to drain while also protecting the wound from the surrounding environment. Relese offers a thicker, specialized allograft with excellent handling characteristics, making it ideal for various clinical applications. StimLabs’ dCHPM portfolio philosophy has always been to protect and retain the valuable structures and components found in birth tissues. Most placental membrane-based products are processed by delaminating and removing one or more layers of the native tissue. These processing techniques can compromise tissue integrity and the preservation of key components.1 Through StimLabs’ patented Clearify™ technology, Relese retains all three layers of the native tissue, key proteins, growth factors, and other components while never delaminating the membrane. “Our team of scientists, researchers, and industry experts has developed a high-quality allograft while addressing specific patient needs. We are confident clinicians will see the impact Relese can have on patients suffering from highly exudating chronic and acute wounds,” says John Daniel, StimLabs’ Founder and CEO. With the introduction of Relese, StimLabs aims to extend its reach to more patients in need of a unique placental membrane-derived solution. About StimLabs For more information about Relese and its reimbursement, please visit www.stimlabs.com.
Media Contact:
SOURCE StimLabs |
View original content to download multimedia: